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Charcot-Marie-Tooth (CMT) disease denotes a large group of genetically heterogeneous hereditary motor and
sensory neuropathies and ranks among the most common inherited neurological disorders. Mutations in the
Myotubularin-Related Protein-2 (MTMR2) or MTMR13/Set-Binding Factor-2 (SBF2) genes are associated with
the autosomal recessive disease subtypes CMT4B1 or CMT4B2. Both forms of CMT share similar features
including a demyelinating neuropathy associated with reduced nerve conduction velocity (NCV) and focally
folded myelin. Consistent with a common disease mechanism, the homodimeric MTMR2 acts as a phospho-
inositide D3-phosphatase with phosphatidylinositol (PtdIns) 3-phosphate and PtdIns 3,5-bisphosphate as
substrates while MTMR13/SBF2 is catalytically inactive but can form a tetrameric complex with MTMR2, result-
ing in a strong increase of the enzymatic activity of complexed MTMR2. To prove that MTMR13/SBF2 is the
disease-causing gene in CMT4B2 and to provide a suitable animal model, we have generated Mtmr13/Sbf2-
deficient mice. These animals reproduced myelin outfoldings and infoldings in motor and sensory peripheral
nerves as the pathological hallmarks of CMT4B2, concomitant with decreased motor performance. The
number and complexity of myelin misfoldings increased with age, associated with axonal degeneration,
and decreased compound motor action potential amplitude. Prolonged F-wave latency indicated a mild
NCV impairment. Loss of Mtmr13/Sbf2 did not affect the levels of its binding partner Mtmr2 and the Mtmr2-
binding Dlg1/Sap97 in peripheral nerves. Mice deficient in Mtmr13/Sbf2 together with known Mtmr2-deficient
animals will be of major value to unravel the disease mechanism in CMT4B and to elucidate the critical func-
tions of protein complexes that are involved in phosphoinositide-controlled processes in peripheral nerves.
INTRODUCTION
Charcot-Marie-Tooth (CMT) disease, also called hereditary
motor and sensory neuropathies (HMSN), comprise a geneti-
cally heterogeneous group of inherited disorders affecting
myelinated axons in the peripheral nervous system (1–3) with
a prevalence of approximately 1:2500 (4). The disease is charac-
terized by progressive distally accentuated muscle weakness and
atrophy. Based on clinical, electrophysiological, and histological
data, CMT has been subdivided into demyelinating and axonal
forms. Demyelinating neuropathies are diagnosed by reduced
nerve conduction velocity (NCV). Axonal loss and muscle
atrophy are also observed most likely as secondary effects due
to the tight interaction and communication between myelinating
Schwann cells, axons and muscle cells (5). Axonal forms of
CMT are characterized by a reduction of the compound
muscle action potential (CMAP) amplitude due to a loss of mye-
linated axons (6). Dissection of the cellular functions of the gene
products altered in CMT as well as the generation of detailed
pathophysiological models are of crucial importance to under-
stand the underlying common as well as distinct disease mech-
anisms which may affect Schwann cells, axons or both (2).
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The subtype CMT4B is a severe demyelinating autosomal
recessive inherited neuropathy with onset in early childhood.
Histological analysis of human nerve biopsies revealed demye-
lination and focally folded myelin as the particular pathological
hallmark (7). The disease was mapped to chromosome 11q22
and 11p15 indicating that mutations in two different genes
lead to indistinguishable pathologies (8–10). Further mapping
refinements and molecular cloning lead to the identification
of Myotubularin-Related-Protein-2 (MTMR2) and MTMR13/
Set-Binding-Factor-2 (SBF2) as the disease causing genes
of CMT4B1 and CMT4B2 (11–13). Mtmr2-deficient mice
have been generated and mimic the pathology of CMT4B1
closely (14,15).
MTMR2 and MTMR13/SBF2 belong to the family of
myotubularin-related proteins (16). This family consists of
14 members in human and orthologues have been found
throughout the eukaryotic kingdom but not in bacteria. Myotu-
bularin, the founding member of the family, has been originally
identified as the disease-causing gene in X-linked myotubular
myopathy (17). The domain signature of MTMRs is defined
by the presence of a phospoinositide (PI)-binding PH-GRAM
(pleckstrin homology-glucosyltransferases, Rab-like GTPase
activators and myotubularins)-homology domain, a phosphatase
domain, and a coiled coil motif. The phosphatase domain was
initially described as a potential protein tyrosine/dual specific
phosphatase, but the PIs (PtdIns)-3-phosphate (P) and
PtdIns-3,5-P2 (with myotubularin phosphatase activity specific
for the D3 position of the inositol ring) have emerged as the
main substrates (16,18). The membrane-associated PtdIns-3-P
and PtdIns-3,5-P2 regulate trafficking in the endosomal–lysoso-
mal pathway suggesting that the disease mechanisms in
MTMR-based diseases are likely to be related to these pro-
cesses. Interestingly, disturbances of regulatory mechanisms
involving PIs seem to become a recurrent theme in CMT
since mutations in FIG4, a D5 phosphatase using PtIns-3,5-P2
as substrate, have been recently described to cause CMT4J (19).
Six members of the myotubularin family, including
MTMR13/SBF2, contain inactivating substitutions in the
phosphatase domain. Catalytically inactive MTMRs can inter-
act with active MTMRs as modulators of the phosphatase
activity, substrate traps or they influence the subcellular local-
ization. Specifically and in addition to the common motifs,
MTMR13/SBF2 contains a classical PtIns-3,4,5-P3-binding
PH domain (20), a DENN (differentially expressed in normal
versus neoplastic) domain and a stretch of 500 amino acids
with no homologies to other proteins (Fig. 1A). MTMR13/
SBF2 exists in cells independently as a homodimer, as well
as in complex with a homodimer of MTMR2 (20–22). The
latter association dramatically increases the enzymatic activity
of the binding partner MTMR2 (20).
Here, we have generated Mtmr13/Sbf2-deficient and Mtmr2//
Mtmr13/Sbf2 double-deficient mice to dissect the role of this
pair of myotubularins in health and disease in vivo.
RESULTS
Gene-trapped disruption of Mtmr13/Sbf2
We have used mouse embryonic stem cells carrying a
gene trap insertion in the Mtmr13/Sbf2 locus (XH212;
Baygenomics Gene Trap Resource) for the generation of an
Mtmr13/Sbf2-deficient mutant mouse line using established
procedures (15). The insertion site of the gene trap cassette
was mapped 1267 bp downstream of exon 14 of Mtmr13/Sbf2
(Fig. 1A). Based on this information, primers I, II and III were
designed to discriminate between different alleles and for gen-
otyping (Fig. 1B). Western-blot analysis of sciatic nerve
lysates of Mtmr13/Sbf2-deficient and wt littermates revealed
that the Mtmr13/Sbf2 protein was absent (Fig. 1C). Mice with
a disruptedMtmr13/Sbf2 allele are viable and were born accord-
ing to Mendelian expectations. No obvious sings of impaired
spermatogenesis were observed in contrast to some Mtmr2
mutants (14). Having this viable Mtmr13/Sbf2 allele at hand,
we generated also Mtmr2//Mtmr13/Sbf2-double deficient mice
by appropriate cross breeding with Mtmr2-deficient mutant
animals (15). These Mtmr2//Mtmr13/Sbf2-double deficient
mice were also viable and born according to Mendelian
Figure 1. Gene trapped disruption of Mtmr13/Sbf2. (A) Ideogram of the
Mtmr13/Sbf2 protein structure (first row) and the Mtmr13/Sbf2 gene (second
row). The gene trap vector and the locus of the gene-trap integration into
intron 14 of Mtmr13/Sbf2 is schematically depicted in rows three and four,
respectively. Arrows marked with I and II represent the forward primers for
the wt and trapped Mtmr13/Sbf2 alleles, respectively, and III the reverse
primer for the genotyping PCR (SA, splice acceptor; beta-geo, beta-
galactosidase and neomycin-resistance fusion gene; pA, polyadenylation
site). (B) Genotyping PCR for homozygous (2/2), or heterozygous (þ/2)
Mtmr13/Sbf2 mutant mice, or wt (þ/þ). (C) Western blot analysis of
sciatic nerve lysates of Mtmr13/Sbf2-deficient (2/2) and wt (þ/þ) control
mice. A rabbit polyclonal antibody was used to detect the 210 kDa Mtmr13/
Sbf2 protein. Purified CBP-tagged Mtmr13/Sbf2 protein from a baculovirus
expression system served as positive control (20). Bands below 210 kDa rep-
resent degradation products of Mtmr13/Sbf2.
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ratios. Upon visual inspection, the behavioral phenotype of both
Mtmr13/Sbf2-deficient and Mtmr2//Mtmr13/Sbf2-double
deficient mice appeared normal compared to control littermates.
Starting at the age of 2 months, however, both mutant lines
showed an unusual but very mild hind limb clamping upon
tail suspension (data not shown). Double-heterozygous
Mtmr2//Mtmr13/Sbf2 mutant animals appeared indistinguish-
able from their wt littermates up to 15 months of age (latest
time point examined).
Expression analysis of Mtmr2, Mtmr13/Sbf2
and Dlg1/Sap97 in sciatic nerves of mutant animals
In a first step, we analysed whether alterations in Mtmr2 or
Mtmr13/Sbf2 expression alter the protein levels of its respective
binding partner in the sciatic nerve of mutant animals. Western
blot analysis of sciatic nerve lysates from 12-month-old animals
revealed that Mtmr2 levels were unchanged in Mtmr13/
Sbf2-deficient mice (Fig. 2A). Vice versa, Mtmr13/Sbf2
levels remained unaltered in Mtmr2-deficient mice (Fig. 2B).
Bolino et al. (14) and Bolis et al. (23) have reported an inter-
action of Mtmr2 with Sap97. They detected also reduced
expression of Sap97 in the sciatic nerves of their strain of
Mtmr2-deficient mice. Here, we confirmed these findings in
our strain of Mtmr2-mutant mice (15). We continued to test
whether loss of Mtmr13/Sbf2 would also reduce the levels of
Sap97 by reasoning that loss of the Mtmr2 interaction partner
Mtmr13/Sbf2 might affect indirectly the interaction between
Mtmr2 and Sap97 within a putative larger complex. However,
the levels of Sap97 were not significantly different to wt in
Mtmr13/Sbf2-deficient mice (Fig. 2C). Consistent with these
findings, we found a comparable reduction of Sap97 in
Mtmr2//Mtmr13/Sbf2-double deficient mice as in Mtmr2-single
mutants (Fig. 2D). We conclude that the interaction of Mtmr13/
Sbf2 with Mtmr2 and the interaction between Mtmr2 and Sap97
are unlikely to be intimately connected. This conclusion was
also supported by co-immunoprecipitation experiments reveal-
ing no apparent differences in the interaction of Mtmr2 with
Sap97 between wt and Mtmr13/Sbf2-deficient sciatic nerves
(data not shown).
Behavioral analysis
Visual examination of both Mtmr13/Sbf2-deficient and
Mtmr2//Mtmr13/Sbf2-double-deficient mice revealed no
obvious signs of tremor or major functional disability,
similar to what we had observed in the Mtmr2-deficient
model of CMT4B1 (15). Therefore, we performed a rotarod
test to assess whether a behavioral difference related to
motor function was detectable using this assay. At the age
of 4 months, Mtmr13/Sbf2-deficient mice were not dis-
tinguishable from wt mice (Fig. 3A). At 12 months of age,
however, Mtmr13/Sbf2 mutant animals showed a significantly
reduced performance compared to their wt control littermates
(Fig. 3B) and similar results were obtained with Mtmr2//
Mtmr13/Sbf2-double-deficient mice (Fig. 3C). No significant
difference between the two mutant strains was observed.
Based on the results at this point, we decided not to perform
further detailed studies on Mtmr2//Mtmr13/Sbf2-double
deficient mice. Qualitatively, we did not observe major
pathology differences compared to the single Mtmr13/Sbf2
mutants (data not shown).
Electrophysiology of peripheral nerves of Mtmr13/
Sbf2-deficient mice
Motor nerve conduction of sciatic nerves was studied in
Mtmr13/Sbf2-deficient mice at the age of 4 and 12 months
(Fig. 4). In 4-month-old animals, the CMAP amplitude was
not significantly different in Mtmr13/Sbf2-deficient mice com-
pared to wt (18.0+3.7 versus 14.0+3.6 mV). At 12 months
of age, however, Mtmr13/Sbf2-deficient mice showed a signifi-
cant reduction of the CMAP (7.3+1.1 versus 16.3+2.2 mV
in wt mice) and a slightly prolonged F-wave latency of
5.1+0.2 ms (4.4+0.1 ms in wt). Such a very mildly pro-
longed F-wave latency was already present in 4-month-old
Mtmr13/Sbf2-deficient animals (4.7+0.2 versus 4.2+0.2 ms
in wt). A tendency towards NCV slowing was not significant
at both ages examined.
Progressive myelin abnormalities in peripheral nerves
of Mtmr13/Sbf2-deficient mice
Focally folded myelin is the histological hallmark of both
CMT4B1 and CMT4B2. Thus, we focused our analysis on
the presence, time course and distribution of focal dysmyelina-
tion. At 4 months of age, Mtmr13/Sbf2-deficient mice showed
numerous sciatic nerve fibres with focally folded myelin
(Fig. 5). Abnormalities included both infoldings and outfold-
ings of the entire myelin sheath which particularly affected
large calibre fibres but also smaller, thinly myelinated fibres.
Non-myelinated fibres appeared normal. At higher magnifi-
cation, sciatic nerve cross sections of mutant mice were lit-
tered with various degrees of dysmyelination ranging from
focal budding of the myelin sheath to multiple or combined
infoldings and outfoldings.
Abnormal myelin structures were first but rather sporadi-
cally observed in the sciatic nerves of Mtmr13/Sbf2-deficient
mice already at the age of 3 weeks (Fig. 6A and B). Irregular
myelin folds were easily detectable although of low com-
plexity. Quantitative analysis of these pathological structures
revealed a significant increase in numbers compared to wt
animals (Fig. 7A). Next, since CMT is usually associated
with a clinically progressive time course, we followed the
qualitative and quantitative progression of the pathology
over time. Thus, we examined sciatic nerves at the age of 4
and 15 months (Fig. 6C–F; Fig. 7A). We found a progressive
increase in both, the complexity (age-dependent tendency to
double and multiple infoldings and outfoldings) as well as
the number of misfolded myelin sheaths in Mtmr13/
Sbf2-deficient animals suggesting that the disease process is
continuous throughout the timeframe analysed. Particularly
in older mice, some signs of axonal damage were recognized
although we did not observe an obvious major loss of myeli-
nated axons. Next we reasoned, considering the suggested
molecular function of myotubularins, that the misfoldings of
myelin observed in Mtmr13/Sbf2-deficient mice might be
due to altered vesicular trafficking and myelin-membrane
overgrowth. This could potentially lead to generally altered
myelin sheath thickness as we have observed in myelin
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mutants with multi-folded myelin extensions in the central
nervous system (24). However, using computer-aided morpho-
metry, we did not detect significant alterations in myelin thick-
ness and axon diameter in Mtmr13/Sbf2-deficient sciatic
nerves (Fig. 7B and C), consistent with our identical previous
findings in Mtrm2-deficient mice (15). In agreement with these
data, we did not observe Schwann cell onion bulb formation as
the classical indicators of demyelination and remyelination.
Figure 2. Western blot analysis of the relative Mtmr13/Sbf2, Mtmr2 and Dlg1/Sap97 levels in sciatic nerve lysates from 12-month-old wt, Mtmr2-deficient
(Mtmr22/2), Mtmr13/Sbf2-deficient (Sbf22/2) and Mtmr2//Mtmr13/Sbf2-double deficient (MTMR22/2 Sbf22/2) mice. Each pool contains the sciatic
nerves from two or three animals. Protein levels of Mtmr13/Sbf2, Mtmr2 and Sap97 were quantified by normalizing the relative protein levels to beta-actin,
illustrated in a bar chart. (A) The relative protein level of Mtmr2 does not differ significantly between wt and Mtmr13/Sbf2-deficient (Sbf22/2) sciatic
nerves. (B) The Mtmr13/Sbf2 expression level shows no difference in Mtmr2-deficient (Mtmr22/2) compared to wt control lysates of sciatic nerves. The
Sap97 protein levels in Mtmr2-deficient (Mtmr22/2) lysates are significantly reduced (P , 0.05, Student’s t-test). (C) The relative protein level of Sap97
protein level is not altered in the lysates of Mtmr13/Sbf2-deficient (Sbf22/2) mice compared to wt control lysates. (D) The relative protein levels of
Mtmr13/Sbf2, Sap97 and Mtmr2 were compared in wt and Mtmr2//Mtmr13/Sbf2-double deficient (MTMR22/2 Sbf22/2) sciatic nerves. As expected, no
expression of Mtmr13/Sbf2 or Mtmr2 protein was found. The Sap97 protein is significantly reduced compared to wt (P , 0.05; Student’s t-test) in the
lysates of the double mutant mice. Error bars indicate the SEM.
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Motor and sensory nerves are affected in
Mtmr13/Sbf2-deficient mice
CMT4B2 is classified as a motor and sensory neuropathy.
Thus, we analysed whether these mixed symptoms were
reflected in pathological aberrations in both motor and
sensory nerves. We chose to examine the ventral roots con-
taining exclusively axons derived from motor neurons and
dorsal roots for sensory axons. In both locations, the patho-
logical hallmarks of myelin misfoldings were barely detect-
able at the age of 4 months (Fig. 8A and B), in contrast to
the more distally (with respect to the neuronal cell bodies)
located sciatic nerve (Fig. 6D) which contains both motor
and sensory axons. These findings indicate that the pathology
is more severe in distal compared to proximal parts of PNS
nerves. At the age of 15 months, myelin misfoldings were pro-
minently visible in ventral and dorsal roots suggesting that
both motor and sensory nerves become affected in a progres-
sive manner over time (Fig. 8C and D).
Complex structures of misfolded myelin in Mtmr13/
Sbf2-deficient mice
In order to get some detailed insights into the fine structure of
aberrant Schwann cell-axon units in our mutant mice, we per-
formed ultrastructural analysis using electron microscopy.
Figure 9 shows a collection of pictures to provide a sampling
overview of the different aberrant structures that we have
observed. The myelin misfoldings invariably originated from
compacted myelin and showed an identical number of
myelin lamellae in both myelin misfoldings and the myelin
sheath they originated from (Fig. 9D, quantitative data not
shown). Within myelin misfoldings, we observed normal
compaction and periodicity of the myelin sheath. In general,
the impression of pathological alterations was dominated
by myelin outfoldings with strongly variable complexity
(Fig. 9A–D). The most common formation consisted of one
or multiple outfoldings of different size adjacent to a myeli-
nated large calibre axon, and multiple outfoldings showed a
tendency to form groups (Fig. 9C). Aberrant myelin loops
were always ensheathed by the plasma membrane of the
related Schwann cell (Fig. 9A). Myelin infoldings were also
prominent. They usually presented as finger-like inversions
of the myelin sheath (Fig. 9E) or circular inclusions within
the myelinated nerve fibre (Fig. 9F). Entraining Schwann
cell cytoplasm on their outer surface, they protrude far into
the axon and displace the axoplasm (Fig. 9E). The formation
of double circles (Fig. 9F and G) is most likely due to the
retrograde inversion of a single infolding since, at higher mag-
nifications, we observed axonal material in the gap between
the inner and outer infolding. Alternatively, the nesting of
two distinct infoldings may have led to the double-circle
appearance.
On electrophysiological examination, older Mtmr13/
Sbf2-deficient mice showed a reduction of the CMAP indicat-
ing axonal loss or damage. Thus, we also carefully looked for
axonal pathology. Degeneration of whole Schwann cell-axon
units (Fig. 9K and L) were not observed in young mutants,
but were sporadically present at 4 months and rather frequent
at 15th month. Lateral dislocation of the axon by myelin
infoldings and vacuolar alteration of the axoplasm (Fig. 9I
and J) was often observed. We occasionally found also myeli-
nated nerve fibres not affected by myelin misfoldings but with
a conspicuous widening of the periaxonal space (Fig. 9H).
The amazing complexity of myelin misfoldings and the con-
sequences for the affected Schwann cell-axon units, however,
Figure 3. Rotarod analysis of wt, Mtmr13/Sbf2-deficient (Sbf22/2) and
Mtmr2//Mtmr13/Sbf2-double deficient (Mtmr22/2 Sbf22/2) mice. Mice
were tested four times per day on four consecutive days, and the time spent
on the rotating rod was plotted versus the trial number. For statistical analysis
a Students t-test was used. Error bars show the SEM. (A) Analysis of
4-months-old Mtmr13/Sbf2-deficient (Sbf22/2) and wt control mice
(n ¼ 6). No significant difference between the two groups was detected. (B)
Analysis of five 12-months-old Mtmr13/Sbf2-deficient (Sbf22/2) mice and
six wt control animals. Trials 2, 5, 6, 7 and 9-15 were significantly different
for P , 0.05. (C) Analysis of Mtmr2//Mtmr13/Sbf2-double deficient
(Mtmr22/2 Sbf22/2) and wt control animals (n ¼ 8). All trials were signifi-
cantly different for P , 0.05.
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can be best appreciated on longitudinal sections (Fig. 9M–P).
Complex myelin formations are preferentially, although
not exclusively, located in the nodal and paranodal regions.
At the same time, misfoldings contain axoplasm-like struc-
tures suggesting the entrainment of axonal parts during their
formation (Fig. 9M and P). Occasionally, misfoldings of the
myelin sheath had a larger diameter than the original nerve
fibre, or lead to spatial disarrangement of the normal fibre
anatomy like affecting the node of Ranvier (Fig. 9N). Relating
these structural changes back to the molecular and cellular
functions (and misfunctions in disease) of MTMR13/SBF2
will be a major challenge for the future. On a pure morpho-
logical level, the pathological observations in Mtmr13/
Sbf2-deficient mice are very reminiscent of our observations
in Mtmr2-deficient animals consistent with the biochemical
finding suggesting a crucial role for a high-molecular
complex containing both MTMR13/SBF2 and MTMR2 in
the biology of myelinated peripheral nerves, possibly in the
regulation of membrane trafficking.
DISCUSSION
We report the generation and analysis of the first animal model
for the human neuropathy CMT4B2 by disruption of Mtmr13/
Sbf2 in mice. To our knowledge, this is also the first animal
model for a genetically inherited human disease caused by
mutations affecting an inactive member of the myotubularin
phosphatase family. The aim of this study was three-fold.
First, we wanted to provide the formal proof that mutations
in Mtmr13/Sbf2 are indeed causative for CMT4B2. Second,
we anticipated that the generation of an animal model for this
particular form of CMT will contribute critically to the dissec-
tion of the underlying disease mechanisms, especially with
regard to the development and the progression of the disorder
but also by providing appropriate means for further cell biologi-
cal and biochemical analysis. Finally, recent reports relying on
the analysis of appropriate CMT animal models have provided
hopeful projections for treatment strategies encouraging the
development of further refined animal models (25–28).
Figure 4. Motor nerve conduction studies of sciatic nerves of 4-month-old (A–C) and 12-month-old animals (D–H). Error bars indicate the SEM. (A) At 4
months of age, Mtmr13/Sbf2-deficient (Sbf22/2) mice showed mild but not significant NCV slowing compared to wt mice (n ¼ 6). (B) In comparison to
wt animals, Mtmr13/Sbf2-deficient (Sbf22/2) mice showed no significant difference in CMAP amplitudes at this age. (C) F-wave latency was slightly but sig-
nificantly increased in Mtmr13/Sbf2-deficient (Sbf22/2) mice compared to wt (P , 0.05 Student’s t-test). (D) At the age of 12 months, Mtmr13/Sbf2-deficient
(Sbf22/2) mice showed still no significant NCV slowing compared to wt mice (n ¼ 8). (E) In comparison to wt animals, Mtmr13/Sbf2-deficient (Sbf22/2)
mice showed now significantly reduced CMAP amplitudes (P , 0.001, Student’s t-test; n¼8). (F) The F-wave latency was slightly but significantly increased
in Mtmr13/Sbf2-deficient (Sbf22/2) mice compared to wt (P , 0.05 Student’s t-test). (G and H) Representative recorded traces after stimulation at the (distal)
ankle from 12-months-old wt and Mtmr13/Sbf2-deficient (Sbf22/2) mice show profiles of CMAP. A filled arrowhead indicates the stimulus and a white arrow-
head indicates the onset of the CMAP elicited. A black arrow indicates the beginning of the F-wave.
2996 Human Molecular Genetics, 2007, Vol. 16, No. 24
Initial analysis of Mtmr13/Sbf2-deficient mice as animal
models for CMT4B2 revealed behavioural deficits in the
rotarod assay not in 4 months but in 12-month-old mice indi-
cating significant motor impairments. This finding is consist-
ent with the general clinical features of CMT4B2 patients
that involve motor and sensory disturbances (11,12). Further
analysis by light microscopy and ultrastructural analysis of
peripheral nerves by electron microscopy showed prominent
and complex myelin infoldings and outfoldings reminiscent
of CMT4B2 (9). Our mouse model allowed us to follow the
development of these pathological features in a temporal
fashion by analysing peripheral nerves at different time
points. Both the number and complexity of the unusual
myelin figures increased gradually over time in a continuous
fashion with little inter-animal variability. Some signs of
axonal damage were also observed, in particular in older
animals. Nevertheless, we did not find obvious evidence for
primary demyelination and remyelination as judged from the
lack of major Schwann cell onion bulb formations in the
mouse mutant nerves up to the age of 15 months (last time
point examined) and no decrease in myelin thickness. Consist-
ent with these findings, we observed only minor signs of
reduced NCV (prolonged F-wave latency). This appears to
be in contrast to the strongly reduced NCV in CMT4B2
patients (9,12). Although the reason for this discrepancy is
not yet clear, it should be noted that animal models for the
related condition CMT4B1, associated with Mtmr2 deficiency,
showed also much milder electrophysiological abnormalities
compared to the corresponding human patients (14,15).
It remains to be determined whether this feature is due to
some specific mechanistic aspects of CMT4B-type neuro-
pathies. Similarly, we did not observe a striking loss of mye-
linated large calibre axons in Mtmr13/Sbf2-deficient mice as
has been reported based on qualitative assessments of sural
nerve biopsies of CMT4B2 patients (9,12). Demyelination
and in particular secondary axonal loss might be more pro-
nounced in humans in these distally accentuated neuropathies
due to basic physiological species differences that include
much longer nerves and the longer life span of humans com-
pared to mice (5). We found, however, a correlation
between the rather poor performance of the mutants in the
functional testing on the rotarod and the reduction of the
CMAP amplitude. Since we did not observe major axonal
loss, we favour the hypothesis that distal conduction block
occurs in a significant proportion of fibres, possibly due to
axonal constrictions by major myelin infoldings. Perinodal
abnormalities may also lead to conduction block in the
affected fibres resulting in reduced CMAP amplitudes.
The progressive formation of aberrant myelin outfoldings
and infoldings is a robust feature caused by both MTMR2
and MTMR13/SBF2-deficiency in human and mice. This
poses the major question how these abnormalities are gene-
rated and lead to disease. The first important conceptual
point in this context concerns the determination of the cell
type(s) which require the correct function of these proteins
in a cell-autonomous or potentially non-cell autonomous
Figure 5. Histological analysis of cross sections of sciatic nerves at 4 months
of age. Wt (A, C) and Mtmr13/Sbf2-deficient (Sbf22/2) (B, D) mice were
compared. Mtmr13/Sbf2-deficient (Sbf22/2) mice show numerous nerve
fibres with putatively redundant myelin loops scattered across the nerve
section. Affected nerve fibres exhibit different morphologies including
myelin sheath outfoldings and infoldings (white arrows in D), and likely
degradation of the axon-Schwann cell unit (white arrowhead in D). Scale
bars for A, B: 100 mm; for C, D: 25 mm.
Figure 6. Time course of morphologic changes indicates a progressive neuro-
pathy in Mtmr13/Sbf2-deficient (Sbf22/2) mice. A qualitative and quantitat-
ive analysis of sciatic nerve cross section was performed at the age of 3 weeks,
4 months and 15 months. Three animals were analysed per age and genotype,
and representative images are shown. At 3 weeks (A and B), mutant animals
already show focally folded myelin (white arrows in B), ranging from mere
‘budding’ (oblique white arrow in B) to a major outfolding of the myelin
sheath (horizontal white arrow in B). At 4 months (C and D) and at 15
months (E and F), mutant mice exhibit numerous nerve fibres with redundant
myelin loops (oblique white arrows in D and F). Progression of the neuropathy
is reflected by an increasing number of affected fibres, a higher morphological
complexity of myelin abnormalities and signs of additional axonal degra-
dation. Focal folding of the myelin sheath may be also observed, albeit very
rarely, in wt littermates, possibly reflecting age-dependent dysmyelination.
Scale bars: 25 mm.
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manner. Although it appears likely from the data presented
here and other reports that myelinating Schwann cells are
malfunctioning in CMT4B1 and CMT4B2, the close inter-
actions between axon and Schwann cells require a careful
direct experimental analysis. Using conditional gene targeting
in the mouse, Bolis et al. (23) have elegantly shown that loss
of MTMR2 is sufficient to cause the typical myelin abnormal-
ities in a Schwann cell-autonomous manner. Complementary
experiments will be necessary to answer this question also
for MTMR13/SBF2.
Although it is not known in detail which signalling cascades
are involved in the molecular pathogenesis of CMT4B1 and
CMT4B2, the related processes involve regulation at various
levels (20,22,29). MTMR13/SBF2 appears to act at least
(i) as a regulator of the MTMR2 phosphatase activity, (ii) as
a protector of the PI substrates, and (iii) as an adaptor regulat-
ing the localization of active MTMR2. Membrane PI-binding
GRAM-PH and PH domains in MTMR2 as well as MTMR13/
SBF2 play a major role in at least some of these processes,
possibly by regulating vesicular and membrane trafficking in
Schwann cells since loss of these proteins is associated with
uncontrolled folding of myelin and CMT4B. Recently,
mutations in the Rho-type GTPase guanine nucleotide
exchange factor (GEF) Frabin/FGD4 have been shown to be
associated with CMT4H characterized by abundant myelin
outfoldings (30,31). In addition to a RhoGEF (DH) domain,
Frabin contains two PH domains and a presumably PI-binding
FYVE domain. It is tantalizing to speculate that the presence
of PI-binding domains in the disease-causing MTMR2,
MTMR13/SBF2 and Frabin/FGD4 genes and the striking cor-
relation with myelin outfoldings might be related to over-
lapping disease mechanisms. Further, how Dlg1/Sap97 and
neurofilament light chain protein as described interaction part-
ners of MTMR2 are involved in the disease process causing
CMT4B remains to be determined (14,32).
In conclusion, we have generated an animal model for
CMT4B2. In combination with the available Mtmr2-mutant
mice, the Mtmr13/Sbf2-deficient animals provide valuable
tools for future mechanistic studies in hereditary neuropathies
characterized by myelin outfoldings and infoldings.
MATERIALS AND METHODS
Generation of Mtmr13/Sbf22/2 mice
The Mtmr13/Sbf2—mutant cell line (XH212) was obtained
from MMRRC / BayGenomics ES Cell Clones (http://
baygenomics.ucsf.edu/cgi-bin/BaySearch.py). Details for
Figure 7. Quantification of myelin misfoldings, whole fibre morphometry and
relation between axon diameter and myelin sheath thickness. (A) Quantifi-
cation of myelinated fibres at 3 weeks, 4 months and 15th month of age.
For each stage, the sciatic nerves were isolated from three mice per genotype.
Two semithin sections per nerve, taken at an interval of 1.5 mM, were used for
quantification. After the total number of fibres had been determined, the pro-
portion of myelinated fibres exhibiting misfolded myelin was calculated.
(B) Relation between axon diameter and myelin sheath thickness of 3-week-
and 4-month-old mice. For each age, the sciatic nerves of three animals per
genotype were analysed. Myelin thickness was determined and plotted as a
function of the corresponding axon diameter. Each line represents the trend
line for one mouse. Slope and intercept did not differ significantly between
wt and Mtmr13/Sbf2-deficient (Sbf22/2) mice at either age. For statistical
analysis, a Student’s t-test was used (, P , 0.05; , P , 0.001). Error
bars show the SEM.
Figure 8. Involvement of proximal motor and sensory nerves in Mtmr13/
Sbf2-deficient mice. Histological analysis of ventral and dorsal roots from
mutant mice at four and 15 months of age. On cross sections from 4-month-old
mutants (A and B), focally folded myelin is only scarcely present. At 15
months, both infoldings and outfoldings of the myelin sheath are present in
dorsal and ventral roots (arrows in C and D), reflecting a progressive involve-
ment of proximal nerves in the neuropathy. Scale bar for (A–D): 25 mm.
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gene-trap mutagenesis (33) in mouse embryonic stem cells can
be found at http://baygenomics.ucsf.edu/protocols/index.html.
The precise insertion of the gene-trap vector (pGT1lxf) in the
ES cell genome was determined by Inverse PCR and DNA
sequencing. The cell line was used for blastocyste injection
(Institute of Laboratory Animal Science, University of
Zu¨rich) to obtain chimeric mice and these were crossed with
C57Bl/6 mice. The offspring resulted in expected mendelian
frequencies (wt: 26.1%; heterozygous: 49.2%; homozygous:
24.7%; n ¼ 412).
Figure 9. Electron microscopic analysis of focally folded myelin and axonal degeneration in sciatic nerve of Mtmr13/Sbf2-deficient mice. The figure shows a
collection of different morphologies at age P21 (A–D), 4 months (E–F, M, O, P), and 15 months (G–L, N). Outfolding of the myelin sheath is the most frequent
type of dysmyelination (A–C). Single or multiple redundant myelin loops are visible adjacent to the original myelinated fibre. The Schwann cell membrane
surrounds both the outfoldings and the Schwann cell-axon unit they arise from. Simple outfoldings and the original myelin sheath share the same periodicity
and number of lamellae (D). Infoldings of the myelin sheath may severely affect the axonal shape by leading to constriction of the axonal cytoplasm (arrow
in E) or by forming extensions giving the cross-sectioned fibre a target-like appearance (F and G). The double circles in F and G likely reflect the retrograde
inversion of infolded myelin loops. Note that the interspaces between the inner and outer infolding and the original myelin sheath show the structure of axonal
cytoplasm (insert in F). Some fibres exhibit both infoldings and outfoldings (G). Apart from abnormalities of the myelin sheath, some fibres show disintegration
or even degradation of the entire Schwann cell-axon unit. We observed widening of the periaxonal space (white arrow in H), vacuolar disruption of the inner
myelin layers (I), compression and lateralization of the axon by massive infoldings (J) and various stages of axonal degeneration (K and L). The white arrow in L
points to residual myelin. Longitudinal sections (M–P) revealed preferential location of myelin abnormalities in the nodal and paranodal segments (white arrow
in M). Note that the aberrant myelin loops ensheath axonal processes and lead to massive disruption of the normal architecture of the node, which here is forced
off the cutting plane (white arrow in N). Infoldings and outfoldings also occur in the internodal segment of the myelinated fibre (white arrowhead in O) or near
the Schmidt-Lantermann incisures (arrows and white arrowhead in P). Scale bars for D: 1 mm, L–P: 5 mm.
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Genotyping PCR
Tail genomic DNA was used for the genotype analysis. Primer
pairs I and III were used to characterize the wt allele. Primer
pairs II and III were used for the detection of the mutated
allele. I: 50-TCA GCA GCC AGG GAA CGG AGA C -30.
II: 50-GGA GCA GAC AAG CCC GTC AGG-30. III:
50-AAG AA GGA AGA AAG ACA GTC CG-30.
Protein expression analysis on mutant
and wt sciatic nerves
Sciatic nerve tissue was dissected, frozen in liquid nitrogen,
pulverized with a chilled mortar and pestle and dissolved in
SDS gel sample buffer (34). Proteins were electophoresed on
10% SDS-polyacrylamide gels, transferred onto a Polyvinyli-
dene fluoride (PVDF) membrane (Millipore), and immuno-
blotted with antibodies against Mtmr13/Sbf2 [1:500; rabbit
polyclonal anti-peptide antibodies raised against the peptide
CKNKLLRASAPGDWES (20)], Mtmr2 [1:500; rabbit poly-
clonal anti-peptide antibodies raised against the peptide
CSTSHSENSVHTKSAS (20)], Dlg1/Sap97 (BD Transduction
Laboratories; 1:1000) and beta-actin (Sigma; 1:5000). After
incubation with goat anti-rabbit horseradish peroxidase-
(Jackson Laboratories; 1:10000) or goat anti-mouse alkaline
phosphatase-conjugated secondary antibodies (Promega;
1:10000), immunoreactive bands were visualized by West
Pico Chemiluminescent Substrate (Pierce) or CDP-Star
(Roche). Blots were quantified using ImageJ software (http://
rsb.info.nih.gov/ij/) and normalized to the beta-actin signal
Rotarod test
Mice were placed on a rotarod apparatus (TSE Systems,
Germany) and the time spent on the rotating rod, rotating
from 4 to 40 rpm, was measured. Four trials per day, every
2 h, on four consecutive days were performed with a
maximal trial length of 10 min.
Neurophysiology
Motor nerve conduction of sciatic nerves was investigated in
anesthesized animals as described previously (35). CMAP
and F-wave were recorded with needle electrodes in the foot
muscles after supramaximal stimulation of the tibial nerve at
the ankle and stimulation of the sciatic nerve at the sciatic
notch. Statistical analysis was performed using Student’s
t-test.
Electron microscopy
Animals were anesthesized and sequentially perfused with
0.25 mg/ml heparin in 0.1 M PBS and a fixative solution
containing 4% PFA and 2% glutaraldehyde in 0.1 M caco-
dylate buffer (pH 7.4). Sciatic nerves were dissected, postfixed
for 24 h at 48C, osmicated for 2 h in 2% osmium tetroxide,
washed in distilled water several times, dehydrated in ascend-
ing acetone and embedded in Spurr’s medium (36). Ninety
nanometer ultrathin sections cut on an Ultracut E microtome
(Reichert-Jung, Heidelberg, Germany) were mounted on copper
grids and contrasted with uranyl acetate and lead citrate.
Digital photographs were taken on a Philips EM 208 S trans-
mission electron microscope using the iTEMw software
(Olympus Soft Imaging Solutions, Muenster, Germany).
Morphometric analysis and quantification
of focally folded myelin
Sciatic nerves from intracardially perfused animals were osmi-
cated and embedded in Spurr’s medium as described above.
Semithin sections (0.5 mm) were stained with alkaline tolui-
dine blue under standardized conditions to obtain identical
results with regard to contrast and colour intensity. Semithin
sections were visualized in a Leica DMRX microscope at
400-fold magnification, and a series of partially overlapping
images covering the cross-sectional area was captured with a
SPOT digital camera (Diagnostic Instruments, Sterling
Heights, MI, USA). In order to obtain a composite image of
the entire cross section, single images were pasted together
using a Gaussian filter. Image processing and morphometric
data collection were performed using the analySISw software
(Olympus Soft Imaging Solutions, Muenster, Germany).
A macro was designed to meet the specific requirements of
morphometric analysis. To discriminate axons and myelin
sheaths, we defined a grey-scale threshold level for axon and
myelin profiles. For each nerve fibre, both axon and myelin
area were measured, and the diameter of axons and myelinated
fibres were mathematically deduced from a circle of an equi-
valent area. Paranodes, Schwann cell nuclei, nerve fibres with
focally folded myelin, and unmyelinated fibres were manually
excluded from morphometry. We analysed two sciatic cross
sections per animal (mutant and wt), and sections were
taken from different levels 1.5 mM apart. For quantification
of dysmyelinated nerve fibres, we determined the total
number of fibres on each cross section, and the proportion
of myelinated fibres showing focally folded myelin was
calculated.
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